AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® IN GENERALIZED MYASTHENIA GRAVIS AT AANEM 2024 Life Science Investing
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares Geography